Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amrik Shah

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Statistics in Medicine|May 20, 2003
A maximum likelihood approach for estimating the QT correction factor using mixed effects modelAmrik Shah, Gerald Hajian
Journal of Medical Internet Research|June 23, 2025
Evaluating the Efficacy of MamaLift Plus Digital Therapeutic Mobile App for Postpartum Depression (SuMMER): Randomized, Placebo-Controlled Pivotal TrialShailja Dixit, Indira Malladi, Sidhartha Shankar, et al.
Alimentary Pharmacology & Therapeutics|February 13, 2025
Challenges in Histological Endpoints for MASH Therapies: An Exercise in Statistical ModellingAmrik Shah, Leigh MacConell, Alexander Liberman, et al.
Journal of Electromyography and Kinesiology : Official Journal of the International Society of Electrophysiological Kinesiology|October 26, 2005
Classification of large array surface myoelectric potentials from subjects with and without low back painSteven I Reger, Amrik Shah, Thomas C Adams, et al.
The American Journal of Cardiology|January 17, 2002
Impact of nonmeasurable borders and variation in cross-section counts on intravascular ultrasound measurement of atherosclerotic plaque volumeIvan P Casserly, Khaled Ziada, Samir Kapadia, et al.
Gastroenterology|April 6, 2007
SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonrespondersChristoph Sarrazin, Regine Rouzier, Frank Wagner, et al.
Contemporary Clinical Trials|July 2, 2019
REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitisVlad Ratziu, Arun J Sanyal, Rohit Loomba, et al.
Journal of Hepatology|February 12, 2025
A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASHStephen A Harrison, Naim Alkhouri, Grisell Ortiz-Lasanta, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Statistics in Medicine|May 20, 2003
A maximum likelihood approach for estimating the QT correction factor using mixed effects modelAmrik Shah, Gerald Hajian
Journal of Medical Internet Research|June 23, 2025
Evaluating the Efficacy of MamaLift Plus Digital Therapeutic Mobile App for Postpartum Depression (SuMMER): Randomized, Placebo-Controlled Pivotal TrialShailja Dixit, Indira Malladi, Sidhartha Shankar, et al.
Alimentary Pharmacology & Therapeutics|February 13, 2025
Challenges in Histological Endpoints for MASH Therapies: An Exercise in Statistical ModellingAmrik Shah, Leigh MacConell, Alexander Liberman, et al.
Journal of Electromyography and Kinesiology : Official Journal of the International Society of Electrophysiological Kinesiology|October 26, 2005
Classification of large array surface myoelectric potentials from subjects with and without low back painSteven I Reger, Amrik Shah, Thomas C Adams, et al.
The American Journal of Cardiology|January 17, 2002
Impact of nonmeasurable borders and variation in cross-section counts on intravascular ultrasound measurement of atherosclerotic plaque volumeIvan P Casserly, Khaled Ziada, Samir Kapadia, et al.
Gastroenterology|April 6, 2007
SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonrespondersChristoph Sarrazin, Regine Rouzier, Frank Wagner, et al.
Contemporary Clinical Trials|July 2, 2019
REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitisVlad Ratziu, Arun J Sanyal, Rohit Loomba, et al.
Journal of Hepatology|February 12, 2025
A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASHStephen A Harrison, Naim Alkhouri, Grisell Ortiz-Lasanta, et al.
Pageof 1